Skip to main content Skip to search Skip to main navigation

FDA: Janet Woodcock becomes acting commissioner

Dr. Janet Woodcock has been appointed as acting commissioner of the FDA. The previous commissioner, Dr. Stephen M. Hahn, stepped down from his role at the start of President Biden's term of office.

Janet Woodcock already has a 30-year career at FDA. Most recently, she led the CDER (US FDA Center for Drug Evaluation and Research). Since May 2020, she has also been responsible for leading Operation Warp Speed to support the development of COVID-19 therapeutics. Woodcock will continue to perform this function.  

As she says, she welcomes the challenge of leading FDA on a transitional basis because: 

"The FDA’s public health work is more critical than ever as we continue to fight this global pandemic." 


Sources:

FDA: Janet Woodcock 

Twitter: Janet Woodcock 

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

News: EMA

EMA: Latest Report on the International GMP Inspection Programme for API Manufacturers

EMA has published a new report on the International Active Pharmaceutical Ingredient Inspection Programme, covering the period 2017–2024. During this time, the number of participating authorities increased from ten to 13. Information was shared on 936 inspected sites and 1,684 inspections.
Read more
News: EMA

EMA Updates Procedure for Coordinating GMP Inspections

EMA has updated its procedure for coordinating GMP inspections for centrally authorised medicinal products. Version 3 has applied since 10 September 2026 and replaces Version 2. The document forms part of the Compilation of Union Procedures on Inspections and Exchange of Information (CoUP), which comprises the EU procedures and templates for GMP and GDP inspections.
Read more
Swissmedic Updates Guidance on GMP Compliance of Foreign Manufacturers

Swissmedic Updates Guidance on GMP Compliance of Foreign Manufacturers

Swissmedic has revised its guidance document “GMP compliance by foreign manufacturers”. The new Version 7.0 has been valid since 7 September 2026. In particular, it introduces new provisions for demonstrating the GMP compliance of manufacturers inspected by the US FDA. 
Read more
Swissmedic Updates Requirements for Cooperation with Pre-Wholesalers

Swissmedic Updates Requirements for Cooperation with Pre-Wholesalers

Swissmedic has revised its Technical Interpretation “Market release and distribution in cooperation with a pre-wholesaler”. The document addresses market release and distribution where a Marketing Authorisation Holder works with a pre-wholesaler (logistics and distribution service provider).
Read more
News: Europe

IPEC Updates Two Guides on Pharmaceutical Excipients

The IPEC Federation has updated two key guides on pharmaceutical excipients. The IPEC Composition Guide for Pharmaceutical Excipients (Version 3, 2026) describes an approach for manufacturers to establish excipient composition profiles. The revised version now covers biotechnology- and fermentation-derived excipients, provides further details on component types and physicochemical characterisation, and includes an example composition profile template.
Read more
Applying the FDA’s 7-Step Model for AI/ML Validation in GMP Environments: One Year Later

Applying the FDA’s 7-Step Model for AI/ML Validation in GMP Environments: One Year Later

Artificial intelligence is becoming increasingly important in GMP-regulated environments, presenting companies with new regulatory challenges. This article summarizes the latest regulatory developments, introduces a validation framework based on the FDA's seven-step model, and outlines initial practical experience with AI/ML validation.

Read more
Previous
Next